Immunological response in subjects who received Astra Zeneca
| Withhold therapy | Continue therapy | Healthy controls | Total | |
| Detectable SARS-CoV2 IgG antibodies* | ||||
| Post second dose | 27/27 (100) | 36/43 (83.7) | 22/22 (100) | 85/92 (92.39) |
| 6 months post (p=0.756) | 21/24 (87.5) | 35/41 (85.4) | 19/24 (79.2) | 75/89 (84.3) |
| Withhold versus continue (p=1.00) | ||||
| Withhold versus healthy controls (p=0.701) | ||||
| Continue vs healthy controls (p=0.517) | ||||
| Post booster vaccine dose | 25/25 (100) | 40/40 (100) | 16/16 (100) | 81/81 (100) |
| Median SARS-CoV2 IgG Ab titre† | ||||
| Post second dose | 14.2 (4.3–48.4) | 5.7 (1.5–20.8) | 7.3 (4.4–15.9) | 7.2 (2.3–23.2) |
| 11.7 (6.8–20.3) | 5.7 (3.4–9.3) | 7.3 (4.9–10.7) | 7.6 (5.7–10.1) | |
| 6 months post (p=0.344‡) | 3.3 (1.7–12.3) | 2.3 (1.3–7.4) | 2.3 (0.9–5.3) | 2.6 (1.3–8.3) |
| Withhold versus continue (p=0.325) | 4.0 (2.4–6.7) | 3.0 (2.0–4.53) | 2.4 (1.5–3.8) | 3.1 (2.4–4.0) |
| Withhold versus healthy controls (p=0.143) | ||||
| Continue versus healthy controls (p=0.577) | ||||
| Post booster vaccine dose (p=0.226‡) | 91.8 (58.9–229.1) | 75.4 (39.0–114.4) | 106.1 (53.5–212.5) | 85.9 (46.4–162.6) |
| Withhold versus continue (p=0.134) | 92.0 (51.7–163.8) | 64.0 (44.6–91.9) | 95.3 (48.2–188.4) | 77.6 (58.9–102.3) |
| Withhold versus healthy controls (p=0.949) | ||||
| Continue versus healthy controls (p=0.203) |
| Immunological response in subjects who received Pfizer | ||||
| Post second dose | 37/44 (84.1) | 31/48 (64.58) | 27/27 (100) | 95/119 (79.83) |
| 6 months post (p=0.226) | 32/35 (91.4) | 34/34 (100) | 18/18 (100) | 84/87 (96.6) |
| Withhold versus continue (p=0.239) | ||||
| Withhold versus healthy controls (p=0.279) | ||||
| Continue versus healthy controls | ||||
| Post booster vaccine dose | 34/34 (100) | 38/38 (100) | 20/20 (100) | 92/92 (100) |
| Withhold versus continue | ||||
| Withhold versus healthy controls | ||||
| Continue versus healthy controls | ||||
| Mean SARS-CoV2 IgG Ab titre† | ||||
| Post second dose | 77.8 (38.7–150) | 60 (17.2–128.4) | 66.7 (52.1–106.7) | 68.4 (35.5–129.4) |
| 65.1 (43.8–96.7) | 45.7 (31.4–66.7) | 85.1 (65.5–117.8) | 60.1 (48.1–75.0) | |
| 6 months post (p=0.001‡) | 12.0 (3.9–35.1) | 3.1 (2.0–8.8) | 10.5 (8.0–17.0) | 7.9 (2.7–15.9) |
| Withhold versus continue (p=0.005) | 9.3 (5.8–15.0) | 4.1 (2.8–5.9) | 11.8 (8.1–17.3) | 7.1 (5.5–9.2) |
| Withhold versus healthy controls (p=0.755) | ||||
| Continue versus healthy controls (p=0.000) | ||||
| Post booster vaccine dose (p=0.235‡) | 103.5 (79.3–202.8) | 154.5 (79.0–378.0) | 254.8 (73.1–371.6) | 147.7 (29.0–298.7) |
| Withhold versus continue (p=0.221) | 118.1 (87.0–160.3) | 163.2 (112.6–236.5) | 189.5 (114.1–314.7) | 149.2 (120.4–184.9) |
| Withhold versus healthy controls (p=0.092) | ||||
| Continue versus healthy controls (p=0.827) | ||||
Data are presented as proportions (%) or median (IQR).
Geometric means and corresponding 95% CI are shown in blue.
*Using Fisher’s exact test with significance cut-off 5%.
†Using Wilcoxon-Mann-Whitney test with significance cut-off 5%.
‡Using Kruskal-Wallis test with significance cut-off 5%.